论文部分内容阅读
为获取高效价的红细胞生成素（ＥＰＯ）单抗，以建立重组人红细胞生成素（ｈＥＰＯ）测定方法。用基因重组的ｈＥＰＯ与小鼠血清白蛋白经Ｎ－羟基琥珀酰亚胺基－３（２－吡啶基二硫）丙酸酯（ＳＰＤＰ）交联后，常规免疫ＢＡＬＢ／ｃ小鼠，并用细胞融合技术制备分泌ｈＥＰＯＭｃＡｂ杂交瘤细胞；用间接ＥＬＩＳＡ和免疫印迹技术将ｈＥＰＯＭｃＡｂ与白色念珠菌胞质抗原的ＭｃＡｂ、嗜肺性军团病杆菌ＭｃＡｂ、ＨＣＶ核心肽ＭｃＡｂ、人μ链ＭｃＡｂ、ＩＦＮ－γＭｃＡｂ的间接ＥＬＩＳＡ同时进行特异性鉴定。经融合后检测，获取一株分泌ｈＥＰＯＭｃＡｂ的杂交瘤细胞系。初步鉴定，ｈＥＰＯＭｃＡｂ针对ｈＥＰＯ间接ＥＬＩＳＡ效价为１０－７（对照腹水为１０－３）；免疫印迹结果显示：此ＭｃＡｂ与基因重组的ｈＥＰＯ在分子量３０００～４０００之间有一条显色带，而其它几种ＭｃＡｂ均为阴性结果。小分子物质经与同种动物（免疫用动物）血清白蛋白交联后用作免疫抗原，可提高小分子物质的免疫原性，容易获取高效价的单克隆抗体。
To obtain high titer erythropoietin (EPO) monoclonal antibodies, a recombinant human erythropoietin (hEPO) assay was established. BALB / c mice are routinely immunized with genetically modified hEPO and mouse serum albumin crosslinked with N-hydroxysuccinimidyl-3 (2-pyridyldithio) propionate (SPDP) Fusion technology was used to prepare hEPOMcAb hybridoma cells; indirect immunoblotting and immunoblotting were used to combine hEPOMcAb with C. albicans McAb, C. pneumophila McAb, HCV core peptide McAb, human μ chain McAb, IFN-γMcAb Indirect ELISA at the same time for specific identification. After fusion detection, a hybridoma cell line secreting hEPOMcAb was obtained. Preliminary identification, hEPOMcAb indirect ELISA titers for hEPO 10-7 (control ascites 10-3); Western blot results show that: this McAb and gene recombinant hEPO in the molecular weight 3000 ~ 4000 between a band, and other Several McAbs are negative results. Small molecules with the same animal (immunization animals) serum albumin after cross-linked as an immune antigen, can improve the immunogenicity of small molecules, easy access to high titer of monoclonal antibodies.